1. Home
  2. TY vs AUPH Comparison

TY vs AUPH Comparison

Compare TY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

HOLD

Current Price

$31.59

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.79

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TY
AUPH
Founded
1929
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TY
AUPH
Price
$31.59
$14.79
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
50.3K
1.1M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
5075.00
EPS
4.78
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$16.53
Revenue Next Year
N/A
$16.24
P/E Ratio
$6.61
$7.16
Revenue Growth
N/A
20.38
52 Week Low
$26.54
$6.83
52 Week High
$35.05
$16.54

Technical Indicators

Market Signals
Indicator
TY
AUPH
Relative Strength Index (RSI) 43.84 55.18
Support Level N/A $14.56
Resistance Level $32.02 $15.23
Average True Range (ATR) 0.61 0.50
MACD -0.02 0.04
Stochastic Oscillator 58.05 69.04

Price Performance

Historical Comparison
TY
AUPH

About TY Tri Continental Corporation

Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: